- Volume
- 5 mL listed; concentration not verified
- Quarterly message
- Advertised saving of $125.82 is not a verified package price
- Dispensing
- Confirm pharmacy, total quantity and beyond-use details
Use the monthly selector's actual figure
Trava's sermorelin listing shows a monthly option at $157.91 and identifies a 5 mL quantity. Those are the source-backed starting points for this review. The injection is assessed separately from Trava's NAD+ products, whose prices and quantities should not be imported into a sermorelin comparison merely because they share the same provider.
The page also displays a message about saving $125.82 with a quarterly package. That wording does not make $125.82 a verified monthly rate or establish the amount due for three months. Ask for the exact quarterly invoice and dated renewal schedule rather than calculating a package from an ambiguous promotional number.
Volume and strength answer different questions
The 5 mL label states volume, while concentration is needed to determine the total amount of sermorelin. The checked offer does not provide enough verified detail for this review to calculate a milligram-based comparison. A competing vial with the same volume is not necessarily the same preparation or an equivalent supply.
Obtain the concentration, total quantity, dispensing pharmacy and beyond-use information from the actual prescription. The clinical instructions should come from the prescriber and pharmacist, not from an interpretation of the monthly selector. A payment period describes an agreement; it does not establish a dosing schedule, expected response or a universal course of care.
Review inclusions before comparing total costs
Trava describes online assessment and prescription fulfillment. Confirm which consultation services, supplies and delivery costs are covered by the chosen $157.91 option, and whether required tests or follow-up visits add to the bill. We have not enrolled or received a patient-specific invoice demonstrating the complete cost of this treatment pathway.
For a quarterly purchase, clarify whether payment is collected in advance and whether any unused portion is refundable after dispensing. Ask how to cancel future orders and when the next shipment is initiated. A plan that appears less expensive over a stated period can still create a larger immediate commitment or less flexibility than a monthly arrangement.
A prescribed compound still needs evidence
The provider's compounding disclosure states that these medications are not FDA-approved. Prescribing access does not change that regulatory status or prove the advertised adult wellness effects. The clinician should explain the evidence relevant to the intended purpose and how any monitoring or reassessment fits into the care plan.
This review did not test Trava's preparation or independently verify its clinical claims. Its practical conclusion is a documented monthly offer with a visible volume label, accompanied by unresolved strength and longer-package details. Keeping those distinctions intact allows a reader to request a useful written quote instead of treating a savings message or vial volume as a substitute for the prescription and full payment terms.
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.